Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 1 hour ago
Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms
about 1 hour ago
Merck & Co. has nixed the phase 2 study of a potential...
Zimmer Biomet buys non-drug pain relief system from Pacira for up to $140M
about 1 hour ago
Pacira BioSciences offloaded its cold-therapy pain relief device to medtech orthopedics specialist...
Biotechs ‘in better position to avoid workforce reductions’ as layoffs continue to ease in Q2’26
about 5 hours ago
A sharp reduction in layoffs continued in the second quarter, extending a...
Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset
about 7 hours ago
Ipsen is on a roll this week, scooping up its second biotech...
Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer’s asset in $2.2B deal
about 10 hours ago
QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for...
Can We Outrun Cancer's Evolution? Why BrYet Is Targeting Cancer-Specific Phenotypes
about 22 hours ago
Genetic instability makes metastatic cancer largely incurable. BrYet aims to work around...
Bain-backed bone specialist Angitia drops lead spinal fusion candidate
about 22 hours ago
Coming on the heels of a $130 million fundraising round just four...
Abivax rebounds from stock drop with safety data for much-hyped colitis prospect
1 day ago
Abivax has recovered from a dent in its share price after unveiling...
FDA gene therapy regulator Vijay Kumar steps down from leadership role
1 day ago
Vijay Kumar, the acting head of the FDA office that oversees new...
China approved the world’s first solid tumor CAR-T therapy. When will the US follow?
1 day ago
CAR-T cell therapy has flourished since it was first used in 2010...
Vistagen fails another phase 3 social anxiety trial but spies path to market
1 day ago
Vistagen’s social anxiety disorder drug candidate has flunked another phase 3 trial...
Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE from China’s Metis TechBio
1 day ago
U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio...